LUMINEX CORPORATION acquired by DIASORIN

Luminex Corporation operates as a premier technology organization dedicated to the engineering and distribution of proprietary biological testing technologies. The entity’s business model is centered on its industry-leading xMAP® multiplexing technology, an open-architecture platform that allows for the simultaneous analysis of hundreds of bioassays from a single droplet of fluid. Its value proposition is anchored in technical operational depth, providing both high-throughput molecular diagnostics and extensive life science solutions that support clinical and pharmaceutical research. Strategically, the firm focuses on the mission-critical needs of hospitals and laboratories worldwide, facilitating rapid and efficient understanding of complex diseases at the protein and genomic levels. By maintaining a specialized focus on technical excellence and market-leading expertise in multiplexed assays, the organization ensures a vital role in the structural advancement of precision medicine. The entity prioritizes industrialized analytical standards to facilitate the structural efficiency of diagnostic workflows.